Slide 1: Turning the Tide in Cancer Therapy
Turning the Tide in Cancer Therapy Plinabulin - Redefining Oncology Efficacy and Tolerability September 2026 NASDAQ: BYSI Non-Confidential
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Company Highlights
Company Highlights Plinabulin: Durable Anti- DUBLIN-4: Confirmatory BYSI: Oncology- cancer Efficacy and Bone Global Phase 3 in Post-ICI focused Global Biotech Marrow Protection NSCLC • Unique MoA • Company Overview GEF-H1–mediated dendritic-cell (DC) • Mechanism-based Population Founded 2010 | New J
Slide 4: Plinabulin: Dual Immunomodulatory and Neutropenia-Mitigating Activity
Plinabulin: Dual Immunomodulatory and Neutropenia-Mitigating Activity Plinabulin releases GEF-H1 from microtubules, promoting dendritic-cell maturation and reducing CIN 1-6 Increase Chemotherapy DC Maturation & Tumor Vasculature Treatment Cycles & APC Activation Modulation Maintain Dose Intensity Re
Slide 5: DUBLIN-4 Targets a Large, Underserved Post-ICI NSCLC Population
DUBLIN-4 Targets a Large, Underserved Post-ICI NSCLC Population Despite strong first-line success, treatment options after progression remain limited ICI annual sales at ~$60 billion; Limited Treatment Options for Post- Projected NSCLC Patient Pool Post-ICI Unmet Need ICI NSCLC without Driver Altera
Slide 6: DUBLIN-3: Phase 3 Foundation for DUBLIN-4
DUBLIN-3: Phase 3 Foundation for DUBLIN-4 DUBLIN-3 Study: 2L/3L EGFR WT NSCLC after progression Established Safety Benefit on platinum therapy N=559 DP with significantly lower Grade 4 Neutropenia • All Cycles Day 8 - Day 8 is ANC nadir for docetaxel R Docetaxel (D) Docetaxel + Plinabulin (DP) Singl
Slide 7: Clinical Efficacy Supports DUBLIN-4 Plinabulin-Mechanism Patient Selection
Clinical Efficacy Supports DUBLIN-4 Plinabulin-Mechanism Patient Selection DUBLIN-3 efficacy in post-ICI subgroup signal and Study 303 prospective study data provide the clinical rationale for DUBLIN-4 in a Plinabulin-mechanism targeted population: • Non-squamous NSCLC + Progressed on ICI DUBLIN-3 P
Slide 8: DUBLIN-4 at a Glance: Confirmatory Global Phase 3 Study, FDA Fast Track Designation
DUBLIN-4 at a Glance: Confirmatory Global Phase 3 Study, FDA Fast Track Designation Docetaxel + Plinabulin vs. Docetaxel in Post-ICI, Driver-Negative Non-Squamous NSCLC N=442 Target Population Endpoints R Post-ICI Non-Squamous NSCLC Primary Double-Blind • Randomized • EGFR / ALK / ROS1 / RET WT 1:1
Slide 9: Plinabulin: One Drug, Multiple Clinical Pipelines
Plinabulin: One Drug, Multiple Clinical Pipelines 700+ patients treated with Plinabulin Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Registration NSCLC Plinabulin + Docetaxel (2nd/3rd line) Plinabulin alone or + CIN Prevention Pegfilgrastim NSCLC (2L/3L) Plinabulin + Pembrolizumab p
Slide 10: Plinabulin: Clear Path to Value Creation in NSCLC & Beyond
Plinabulin: Clear Path to Value Creation in NSCLC & Beyond From Clinical Evidence to DUBLIN-4 and Commercial Potential + + DIFFERENTIATED ASSET PHASE 3 OPPORTUNITY VALUE CREATION Clinical & Safety Evidence DUBLIN-4 – MoA targeted Market & Commercial Path NSCLC post-ICI • Novel GEF-H1 mechanism • 442
Slide 11: Experienced Leadership and SAB Support to Drive Successful Clinical Execution
Experienced Leadership and SAB Support to Drive Successful Clinical Execution Min Qiu June Lu, PhD Na Li John Mao, PhD Helein Li, MD Hao Zhang Joy Jia Chief Executive Officer Chief Scientific Officer Chief Financial Officer SVP, Development VP, Clinical Science Senior Director, CMC VP, Finance Bioph
Slide 12: Complementary Board with Finance, Strategic and Business Excellence
Complementary Board with Finance, Strategic and Business Excellence Brendon Delaney Jen Majeti, PhD, MBA Lan Huang, PhD Mathew Kirkby, MA Patrick Fabbio Sihai Xu, MBA Director Vice Chairman Co-Founder & Chairman Director Director Director Seasoned commercial leader Biotech investor and Biotech entre
Slide 13: Create The Glue, Capture The Protein, Eliminate The Disease
Create The Glue Capture The Protein Eliminate The Disease De Novo Molecular Glues for Protein Targets Beyond the Reach of Traditional Therapies
Slide 14: SEED Was Co-founded By Pioneers in Targeted Protein Degradation and Eli Lilly
SEED Was Co-founded By Pioneers in Targeted Protein Degradation and Eli Lilly ⬢ SEED’s differentiation with Target-centric approach to use novel E3s to degrade undruggable targets ➢ Scientific capability to use >600 E3 ligases, which consists only 2 structural classes of HECT and RING, solved first
Slide 15: Elimination, Not Inhibition, Is The Next Therapeutic Paradigm
Elimination, Not Inhibition, Is The Next Therapeutic Paradigm Molecular glue Disease-causing protein Ub The ubiquitin-proteasome system (UPS) Ub E2 evolved to tag and destroy aberrant E2 proteins with exquisite selectivity, E3 E3 compounded by molecular glues for precision Critical challenge #2 Ub D
Slide 16: SEED Built The TPD 2.0 Engine To Find The Optimal Ligase
SEED Built The TPD 2.0 Engine To Find The Optimal Ligase and Degrade Any Disease-causing Protein SEED's RITE3 platform unlocks access to more than 600 ligases encoded in the human genome. Then designs custom molecular glues to bind them. More ligases. Better matches. Higher hit rates. Pathogenic Pro
Slide 17: SEED's Internal Pipeline Spans Three Therapeutic Areas
SEED’s Internal Pipeline Spans Three Therapeutic Areas SEED Therapeutics is advancing 5 wholly-owned programs in oncology, neurodegeneration, and immunology, powered by 4 novel E3 ligases discovered on our proprietary platform. ONCOLOGY ONCOLOGY NEURODEGENERATION NEURODEGENERATION IMMUNOLOGY RBM39 U
Slide 18: RBM39 is a Master Regulator of Oncogenic Splicing
RBM39 is a Master Regulator of Oncogenic Splicing BIOLOGY ⬢ Master regulator of oncogenic RNA Why it matters splicing programs essential for tumor survival ⬢ Splicing machinery is non-enzymatic and historically undruggable MECHANISM ⬢ Molecular glue-mediated degradation via Why it works DCAF15 selec
Slide 19: Clinical Success Path for ST-01156: Validated Target, Differentiated Molecule, Proven Team
Clinical Success Path for ST-01156: Validated Target, Differentiated Molecule, Proven Team Three independent layers of evidence (target, molecule, team) support a high probability of clinical success. 1 VALIDATED TARGET 2 DIFFERENTIATED MOLECULE 3 PROVEN TEAM RBM39 ST-01156 Execution Biology, struct
Slide 20: ST-01156: RBM39 Opportunity Across >1 Million Addressable Patients
ST-01156: RBM39 Opportunity Across >1 Million Addressable Patients And Supported by Complete Tumor Regression and FDA Designations Complete tumor regression in Ewing Sarcoma 3500 3000 Tumor volume (mm3) 2500 Sarcoma Hepatocellular Colorectal Cancer 2000 Rare pediatric and Carcinoma 1500 orphan cance
Slide 21: Highly Experienced Board of Directors
Highly Experienced Board of Directors Lan Huang, PhD James Tonra, PhD Linus Lin, PhD Yoshiharu Mizui, PhD Jackson Tai Ko-Yung Tung, JD Co-Founder, CEO and President, CSO and Director Director Director Director Director Chairman 20+ years of drug discovery AVP of Molecular Discovery Founder and Presi
Slide 22: World-Class Scientific Advisory Board
World-Class Scientific Advisory Board Avram Hershko, MD Ning Zheng, PhD Michele Pagano, MD Co-Founder Co-Founder Co-Founder Founding Godfather' of TPD; 2004 Nobel HHMI Investigator; Professor of HHMI Investigator; Chair of Science: Laureate; Distinguished Professor at Pharmacology, University of Bio
Slide 23: Breakthrough Investments Highlight the Value of Molecular Glues and Degraders
Breakthrough Investments Highlight the Value of Molecular Glues and Degraders Discovery stage TPD assets Upfront payments of $35M - $60M and Novartis Sticks With Orionis in Second Deal: $500M - $5B in potential milestones. $40M upfront with total value up to $1.4B Pre-IND / IND stage TPD assets $100
Slide 24: SEED Therapeutics – Category-defining Molecular Glue Company
SEED Therapeutics – Category-defining Molecular Glue Company 1 Molecular glue field with clinical validation + value recognition 4 Clinical proof of mechanism in RBM39 target engagement ST-01156, novel RBM39 degrader: Rapid enrollment with leading U.S. institutions, Molecular glue and TPD validation
Slide 25: Thank You
Thank You General Inquiries: GENERAL@beyondspringpharma.com Investor: IR@beyondspringpharma.com Media: PR@beyondspringpharma.com www.beyondspringpharma.com